We were delighted to meet with Martin Hoenigl (University of California San Diego, San Diego, USA & Medical University of Graz, Graz, Austria) to discuss the interim analysis from a phase 3 study, investigating ibrexafungerp in patients with refractory fungal diseases.
The abstract entitled: ‘Outcomes of oral ibrexafungerp in 33 patients with refractory fungal diseases, interim analysis of a phase III open-label study (FURI)’ was presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).
Questions:
- What is the mechanism of action of ibrexafungerp and why does it appear to be such a promising new antifungal agent? (0:21)
- What were the aims, design, and eligibility criteria of the FURI study? (2:42)
- What have been the efficacy and safety findings of the study to date? (5:11)
- What will be the clinical impact of ibrexafungerp, if approved for patients with refractory or intolerant fungal diseases? (6:31)
Disclosures: Martin Hoenigl has received research support from Gilead, Astellas, Pfizer, Scynexis, F2G and NIH.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed in coverage of the 31st ECCMID Congress 2021.
